Lee Yung, Raveendran Lucshman, Lovrics Olivia, Tian Chenchen, Khondker Adree, Koyle Martin A, Farcas Monica, Doumouras Aristithes G, Hong Dennis
Division of General Surgery, McMaster University, Hamilton, ON, Canada.
Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Can Urol Assoc J. 2021 Oct;15(10):E553-E562. doi: 10.5489/cuaj.7109.
Obesity (body mass index [BMI] >35 kg/m) remains a relative contraindication for kidney transplant, while patients after kidney transplantation (KTX) are predisposed to obesity. The present study aims to investigate the role of bariatric surgery in improving transplant candidacy in patients prior to KTX, as well its safety and efficacy in KTX patients postoperatively.
A systematic search was conducted up to March 2020. Both comparative and non-comparative studies investigating the role of bariatric surgery before or after KTX were considered. Outcomes included change in BMI, rates of mortality and complications, and the rate of patients who underwent KTX following bariatric surgery. Pooled estimates were calculated using the random effects meta-analysis of proportions.
Twenty-one studies were eligible for final review; 11 studies investigated the role of bariatric surgery before KTX. The weighted mean BMI was 43.4 (5.7) kg/m at baseline and 33.9 (6.3) kg/m at 29.1 months followup. After bariatric surgery, 83% (95% confidence interval [CI] 57-99) were successfully listed for KTX and 83% (95% CI 65-97) of patients subsequently received successful KTX. Ten studies investigated the role of bariatric surgery after kidney transplant. Weighted mean baseline BMI was 43.8 (2.2) kg/m and mean BMI at 19.5 months followup was 34.2 (6.7) kg/m. Overall, all-cause 30-day mortality was 0.5% for both those who underwent bariatric surgery before or after receiving a KTX. The results of this study are limited by the inclusion of only non-randomized studies, limited followup, and high heterogeneity.
Bariatric surgery may be safe and effective in reducing weight to improve KTX candidacy in patients with severe obesity and can also be used safely following KTX.
肥胖(体重指数[BMI]>35kg/m²)仍是肾移植的相对禁忌证,而肾移植(KTX)后的患者易患肥胖症。本研究旨在探讨减肥手术在改善KTX术前患者移植候选资格方面的作用,以及其在KTX术后患者中的安全性和有效性。
截至2020年3月进行了系统检索。纳入了调查减肥手术在KTX前后作用的比较性和非比较性研究。结果包括BMI的变化、死亡率和并发症发生率,以及减肥手术后接受KTX的患者比例。使用随机效应比例荟萃分析计算合并估计值。
21项研究符合最终审查标准;11项研究调查了减肥手术在KTX术前的作用。基线时加权平均BMI为43.4(5.7)kg/m²,随访29.1个月时为33.9(6.3)kg/m²。减肥手术后,83%(95%置信区间[CI]57-99)的患者成功列入KTX候选名单,随后83%(95%CI 65-97)的患者成功接受了KTX。10项研究调查了减肥手术在肾移植后的作用。加权平均基线BMI为43.8(2.2)kg/m²,随访19.5个月时平均BMI为34.2(6.7)kg/m²。总体而言,接受KTX术前或术后进行减肥手术的患者30天全因死亡率均为0.5%。本研究结果受到仅纳入非随机研究、随访有限和高度异质性的限制。
减肥手术在减轻体重以改善严重肥胖患者的KTX候选资格方面可能是安全有效的,并且在KTX术后也可安全使用。